Table 1 Drugs of clinical trials for HR neuroblastoma interventetion

NCT00026312

Isotretinoin With or Without Dinutuximab, Aldesleukin and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

phase III

Completed

Yu AL et al., 2010 [6]

NCT01704716

High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)

phase III

Recruiting

Dobrenkov K & Cheung NK, 2014 [7]

NCT01822652

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

phase I

Active, not recruiting

Heczey A & Louis CU, 2013 [8]

NCT02395666

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

Phase 2

Active, not recruiting

Wallick CJ et al., 2005 [64]

NCT01586260

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Phase 2

Active, not recruiting

Wallick CJ et al., 2005 [64]

NCT01059071

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Phase 1

Completed

Wallick CJ et al., 2005 [64]

NCT02097810

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1 or ALK Molecular Alterations

phase I

Recruiting

Lee J et al., 2015 [83]

NCT01742286

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

phase I

Recruiting

Schulte JH et al., 2013 [69]

NCT01871805

A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer

phase II

Active, not recruiting

McKeage K, 2015 [86]

NCT01049841

Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

phase I

Active, not recruiting

Rodrik-Outmezguine VS et al., 2011 [104]

NCT01767194

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Phase 2

Recruiting

Geoerger B et al., 2012 [105]